Pipeline & Disease Focus

Bioniz technology allows development of novel peptide-based therapeutics that selectively inhibits multiple cytokines in a cytokine family. Our lead program is focused on targeting the common-gamma receptor (CD132). Bioniz has several assets that selectively inhibit some, but not all, of the cytokines in this family. Each antagonistic peptide has a unique spectrum of cytokine inhibition. Some peptides selectively inhibit the functions of IL-2, IL-9 and IL-15 and some block IL-15 and IL-21. Bioniz lead peptide, BNZ132-1, blocks IL-2, IL-9, and IL-15 and is in clinical development path stage for the treatment of an orphan neuro-inflammatory disease called HAM/TSP.